Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis

International Journal of Cancer

Volumn 137, Issue 4, 2015, Pages 797-809

  Haduong, Josephine H ^a,b   Blavier, Laurence ^a,b   Baniwal, Sanjeev K ^b   Frenkel, Baruch ^b,c   Malvar, Jemily ^a   Punj, Vasu ^d   Sposto, Richard ^a,b   DeClerck, Yves A ^a,b,c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

mesenchymal cells; neuroblastoma; osteoblastogenesis; VEGFA

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RUNX2; VASCULOTROPIN A; CORE BINDING FACTOR ALPHA 1 SUBUNIT; RNA, MESSENGER; RUNX2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW STROMA CELL; CELL DIFFERENTIATION; CELL INTERACTION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; MESENCHYMAL STROMA CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; OPG GENE; OSTEOCLASTOGENESIS; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANKL GENE; RUNX2 GENE; UPREGULATION; VEGFA GENE; ANIMALS; BIOSYNTHESIS; CELL LINE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETICS; HUMANS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; METABOLISM; MICE; NEUROBLASTOMA; OSTEOBLASTS;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CORE BINDING FACTOR ALPHA 1 SUBUNIT; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LYMPHOCYTE ACTIVATION; MESENCHYMAL STROMAL CELLS; MICE; NEUROBLASTOMA; OSTEOBLASTS; OSTEOPROTEGERIN; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84931564299     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29465     Document Type: Article

References (44)

1. Roodman GD,. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64. doi: 10.1056/NEJMra030831. PubMed PMID: 15084698.
2. Weilbaecher KN, Guise TA, McCauley LK,. Cancer to bone: a fatal attraction. Nat Rev Cancer 2011; 11: 411-25. doi: 10.1038/nrc3055. PubMed PMID: 21593787; PubMed Central PMCID: PMC3666847.
3. Guise TA, Mundy GR,. Cancer and bone. Endocr Rev 1998; 19: 18-54. doi: 10.1210/edrv.19.1.0323. PubMed PMID: 9494779.
4. Sohara Y, Shimada H, DeClerck YA,. Mechanisms of bone invasion and metastasis in human neuroblastoma. Cancer Lett 2005; 228: 203-9. doi: 10.1016/j.canlet.2005.01.059. PubMed PMID: 15975706.
5. Roodman GD,. Biology of osteoclast activation in cancer. J Clin Oncol 2001; 19: 3562-71. PubMed PMID: 11481364.
6. Mendez-Ferrer S, Michurina TV, Ferraro F, et al., Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010; 466: 829-34. doi: 10.1038/nature09262. PubMed PMID: 20703299; PubMed Central PMCID: PMC3146551.
7. Hall CL, Keller ET,. The role of wnts in bone metastases. Cancer Metastasis Rev 2006; 25: 551-8. doi: 10.1007/s10555-006-9022-2. PubMed PMID: 17160558.
8. Sethi N, Dai X, Winter CG, et al., Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19: 192-205. doi: 10.1016/j.ccr.2010.12.022. PubMed PMID: 21295524; PubMed Central PMCID: PMC3040415.
9. Gazit D, Ebner R, Kahn AJ, et al., Modulation of expression and cell surface binding of members of the transforming growth factor-beta superfamily during retinoic acid-induced osteoblastic differentiation of multipotential mesenchymal cells. Mol Endocrinol 1993; 7: 189-98. doi: 10.1210/mend.7.2.8385738. PubMed PMID: 8385738.
10. Phimphilai M, Zhao Z, Boules H, et al., BMP signaling is required for RUNX2-dependent induction of the osteoblast phenotype. J Bone Miner Res 2006; 21: 637-46. doi: 10.1359/jbmr.060109. PubMed PMID: 16598384; PubMed Central PMCID: PMC2435171.
11. Maris JM, Hogarty MD, Bagatell R, et al., Neuroblastoma. Lancet 2007; 369: 2106-20. doi: 10.1016/S0140-6736(07)60983-0. PubMed PMID: 17586306.
12. Cheung NK, Dyer MA,. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer 2013; 13: 397-411. doi: 10.1038/nrc3526. PubMed PMID: 23702928.
13. Granchi D, Amato I, Battistelli L, et al., In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 2004; 111: 829-38. doi: 10.1002/ijc.20308. PubMed PMID: 15300794.
14. Michigami T, Ihara-Watanabe M, Yamazaki M, et al., Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res 2001; 61: 1637-44. PubMed PMID: 11245477.
15. Sohara Y, Shimada H, Minkin C, et al., Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res 2005; 65: 1129-35. doi: 10.1158/0008-5472.CAN-04-2853. PubMed PMID: 15734993.
16. Bergfeld SA, Blavier L, Declerck YA,. Bone Marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther 2014; 13: 962-975.
17. Baniwal SK, Shah PK, Shi Y, et al., Runx2 promotes both osteoblastogenesis and novel osteoclastogenic signals in ST2 mesenchymal progenitor cells. Osteoporos Int 2012; 23: 1399-413. doi: 10.1007/s00198-011-1728-5. PubMed PMID: 21881969.
18. Sohara Y, Shimada H, Scadeng M, et al., Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate. Cancer Res 2003; 63: 3026-31. PubMed PMID: 12810621.
19. Klement G, Baruchel S, Rak J, et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Investig 2000; 105: R15-24. doi: 10.1172/JCI8829. PubMed PMID: 10772661; PubMed Central PMCID: PMC517491.
20. Kerbel RS, Viloria-Petit A, Klement G, et al., 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000; 36: 1248-57. PubMed PMID: 10882863.
21. Das B, Yeger H, Tsuchida R, et al., A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 2005; 65: 7267-75. doi: 10.1158/0008-5472.CAN-04-4575. PubMed PMID: 16103078.
22. Tang W, Yang F, Li Y, et al., Transcriptional regulation of vascular endothelial growth factor (VEGF) by osteoblast-specific transcription factor osterix (osx) in osteoblasts. J Biol Chem 2012; 287: 1671-8. doi: 10.1074/jbc.M111.288472. PubMed PMID: 22110141; PubMed Central PMCID: PMC3265850.
23. Liu Y, Berendsen AD, Jia S, et al., Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Investig 2012; 122: 3101-13. doi: 10.1172/JCI61209. PubMed PMID: 22886301; PubMed Central PMCID: PMC3428080.
24. Ara T, Song L, Shimada H, et al., Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009; 69: 329-37. doi: 10.1158/0008-5472.CAN-08-0613. PubMed PMID: 19118018; PubMed Central PMCID: PMC2761219.
25. Tian E, Zhan F, Walker R, et al., The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483-94. doi: 10.1056/NEJMoa030847. PubMed PMID: 14695408.
26. Kakonen SM, Mundy GR,. Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 2003; 97 (3 Suppl): 834-9. doi: 10.1002/cncr.11132. PubMed PMID: 12548583.
27. Hall CL, Bafico A, Dai J, et al., Prostate cancer cells promote osteoblastic bone metastases through wnts. Cancer Res 2005; 65: 7554-60. doi: 10.1158/0008-5472.CAN-05-1317. PubMed PMID: 16140917.
28. Cao X, Chen D,. The BMP signaling and in vivo bone formation. Gene 2005; 357: 1-8. doi: 10.1016/j.gene.2005.06.017. PubMed PMID: 16125875; PubMed Central PMCID: PMC2667963.
29. Nishimura R, Hata K, Matsubara T, et al., Regulation of bone and cartilage development by network between BMP signalling and transcription factors. J Biochem 2012; 151: 247-54. doi: 10.1093/jb/mvs004. PubMed PMID: 22253449. [PMC][10.1093/jb/mvs004] [22253449]29.
30. Logothetis CJ, Lin SH,. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5: 21-8. doi: 10.1038/nrc1528. PubMed PMID: 15630412.
31. Kakonen SM, Selander KS, Chirgwin JM, et al., Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002; 277: 24571-8. doi: 10.1074/jbc.M202561200. PubMed PMID: 11964407.
32. Theriault RL, Lipton A, Hortobagyi GN, et al., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 aredia breast cancer study group. J Clin Oncol 1999; 17: 846-54. PubMed PMID: 10071275.
33. Lluch A, Cueva J, Ruiz-Borrego M, et al., Zoledronic acid in the treatment of metastatic breast cancer. Anticancer Drugs 2014; 25: 1-7. doi: 10.1097/CAD.0000000000000020. PubMed PMID: 24100278.
34. Bu G, Lu W, Liu CC, Selander K, Yoneda T, Hall C, Keller ET, Li Y,. Breast cancer-derived Dickkopf1 inhibits osteoblast differentiation and osteoprotegerin expression: implication for breast cancer osteolytic bone metastases. Int J Cancer 2008; 123: 1034-42. doi: 10.1002/ijc.23625. PubMed PMID: 18546262; PubMed Central PMCID: PMC3732167.
35. Mercer RR, Miyasaka C, Mastro AM,. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis 2004; 21: 427-35. PubMed PMID: 15672867.
36. Mastro AM, Gay CV, Welch DR, et al., Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem 2004; 91: 265-76. doi: 10.1002/jcb.10746. PubMed PMID: 14743387.
37. Fontanini G, Lucchi M, Vignati S, et al., Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6. PubMed PMID: 9196255.
38. Speirs V, Atkin SL,. Production of VEGF and expression of the VEGF receptors Flt-1 and KDR in primary cultures of epithelial and stromal cells derived from breast tumours. Br J Cancer 1999; 80: 898-903. doi: 10.1038/sj.bjc.6690438. PubMed PMID: 10360672; PubMed Central PMCID: PMC2362274.
39. Mayr-Wohlfart U, Waltenberger J, Hausser H, et al., Vascular endothelial growth factor stimulates chemotactic migration of primary human osteoblasts. Bone 2002; 30: 472-7. PubMed PMID: 11882460.
40. Zelzer E, McLean W, Ng YS, et al., Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development 2002; 129: 1893-904. PubMed PMID: 11934855.
41. Zelzer E, Olsen BR,. Multiple roles of vascular endothelial growth factor (VEGF) in skeletal development, growth, and repair. Curr Top Dev Biol 2005; 65: 169-87. doi: 10.1016/S0070-2153(04)65006-X. PubMed PMID: 15642383.
42. Fukaya Y, Shimada H, Wang LC, et al., Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008; 283: 18573-81. doi: 10.1074/jbc.M803115200. PubMed PMID: 18450743.
43. Silverman AM, Nakata R, Shimada H, et al., A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res 2012; 72: 2228-38. doi: 10.1158/0008-5472.CAN-11-2165. PubMed PMID: 22389450; PubMed Central PMCID: PMC3815584.
44. Piccolo E, Tinari N, Semeraro D, et al., LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis. J Mol Med 2013; 91: 83-94. doi: 10.1007/s00109-012-0936-6. PubMed PMID: 22864925.